/
RSS Feed
STEVEN GRINSPOON, Massachusetts General Hospital, Boston
COMMENT: JUDITH CURRIER, University of California, Los Angeles
REFERENCE: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
Daily administration of an analog of growth hormone releasing factor to HIV patients receiving highly active antiretroviral therapy significantly decreased visceral fat and improved their lipid profiles. This development-stage drug, TH9507, was well tolerated and may help patients reduce central fat accumulation and abnormal lipid profiles, both of which are known cardiovascular risk factors. In addition, decreases in central fat may have a positive effect on patients’ self-image. Steven Grinspoon gave Dan Keller details during the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles.
[audio:https://www.audiomedica.com/podcasting/global_health/022607_Grinspoon.mp3] Daily administration of an analog of growth hormone releasing factor to HIV patients receiving highly active antiretroviral therapy significantly decreased visceral fat and improved their lipid profiles. This development-stage drug, TH9507, was well tolerated and may help patients reduce central fat accumulation and abnormal lipid profiles, both of which are known cardiovascular risk factors. In addition, decreases in central fat may have a positive effect on patients’ self-image. Steven Grinspoon gave Dan Keller details during the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles.
